ArticleeLife2021

End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies.

Richard Venz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.